Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density
NCT00446589 · Papageorgiou General Hospital · PHASE4 · terminated · last registry update 2014-10-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to financial problems” | – | Registry record, Papageorgiou General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-09-25Phase 3 first posted: Hoffmann-La Roche, Ibandronate (NCT02561039)
- 2015-08-05Phase 3 first posted: Alliance for Clinical Trials in Oncology, ixazomib + lenalidomide (NCT02516423)
- 2015-07-21Phase 3 first posted: Axsome Therapeutics, Inc., AXS-02 (oral zoledronate) + Placebo (NCT02504008)
- 2014-11-10Results posted on the registry: Radiation Therapy Oncology Group, zoledronic acid + Sm-153 (NCT00365105)
- 2014-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, zoledronic acid + androgen deprivation therapy (NCT00079001)
- 2014-09-03Phase 3 first posted: Milton S. Hershey Medical Center, Alendronate + Placebo (NCT02230332)
- 2014-07-28Results posted on the registry: James J. Peters Veterans Affairs Medical Center, Zoledronic acid (NCT02042872)
- 2014-07-22Results posted on the registry: Organon and Co, alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus) + Calcitriol (NCT01350934)
- 2014-07-10Phase 3 first posted: University of Nebraska, Calcium Carbonate + Vitamin D3 (NCT02186600)
- 2014-07-03Results posted on the registry: Susan L. Greenspan, risedronate (NCT00485953)
- 2014-06-06Results posted on the registry: Barbara Ann Karmanos Cancer Institute, zoledronate therapy (NCT01205646)
- 2014-05-12Results posted on the registry: University of Wisconsin, Madison, Zometa + zometa (NCT00582556)
- 2014-04-25Phase 3 first posted: Carmen Gómez-Vaquero, Zoledronic acid (NCT02123264)
- 2014-04-15Phase 3 first posted: Brigitte Jolles, MD, ibandronate + Placebo (NCT02114489)
- 2014-04-09Results posted on the registry: Amgen, Denosumab + Zoledronic Acid (NCT00330759)
- 2014-03-21Results posted on the registry: Amgen, zoledronic acid + denosumab (NCT00321620)
- 2014-03-10Results posted on the registry: Amgen, Denosumab + Zoledronic Acid (NCT00321464)
- 2014-02-14Phase 3 first posted: Takeda, NE-58095 IR + NE-58095 IR Placebo (NCT02063854)
- 2014-01-22Results posted on the registry: Organon and Co, MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (NCT01437111)
- 2014-01-07Results posted on the registry: Amgen, alendronate + denosumab (NCT00518531)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision